Drug Discovery for Neurodegeneration

描述（由申请人提供）：阿尔茨海默病药物发现基金会（ADDF）申请U13合作协议会议拨款，以支持定于2013年2月10日至12日在加利福尼亚州旧金山举行的神经退行性疾病药物发现会议。该申请是对资助号2U13AG031125-o5的竞争续期。会议的目的是通过培训将基础研究转化为新疗法的下一代科学领袖，推进神经退行性疾病的药物发现。关于这一主题的正规教育是必要的，因为在这一研究领域存在记录在案的知识缺口，而且在制药行业之外，了解这些过程的机会很少。这次教学会议的目标显然与NIH的路线图一致：弥合药物发现和神经退行性疾病方面的知识差距；将跨学科的科学家聚集在一起，激发结合技能和学科的新方法；并为这些科学家提供交流思想和资源的网络机会。本次会议将为与会者提供有关创造治疗和预防神经退行性疾病的新药的基本知识和资源。它将解决与以下子主题相关的障碍和挑战：药物化学基础；药物发现：从筛选到临床候选药物挑战中枢神经系统靶点的生物制剂商业化战略：将科学转化为产品。有关阿尔茨海默病，帕金森病，肌萎缩侧索硬化症和多发性硬化症的例子将包括在讨论中。会议将包括20-30分钟的演讲，并有充足的时间进行问答、交流和青年研究人员的海报展示。关于路线图的公私伙伴关系倡议，ADDF将邀请来自学术界、工业界和NIH的27名国际知名科学家担任主席或演讲。预计这次会议将为来自不同背景的150名科学家提供服务，包括妇女、少数民族、年轻/初级研究人员和研究生。

DESCRIPTION (provided by applicant): The Alzheimer's Drug Discovery Foundation (ADDF) requests a U13 Cooperative Agreement conference grant in support of its Drug Discovery for Neurodegeneration conference, scheduled for February 10-12, 2013 in San Francisco, CA. The application is a competitive renewal of grant number: 2U13AG031125-o5. The purpose of the meeting is to advance drug discovery for neurodegenerative disease by training the next generation of scientific leaders on the process of translating basic research into novel therapeutics. Formal education on this topic is needed because there is a documented knowledge gap in this area of research and there are very few opportunities outside of the pharmaceutical industry to learn about these processes. The goals of this didactic conference are clearly consistent with the NIH's Roadmap: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; and to provide networking opportunities for these scientists to exchange ideas and resources. This conference will give participants fundamental knowledge and resources on creating new drugs to treat and prevent neurodegenerative disease. It will address the barriers and challenges associated with the following sub-topics: Basics of Medicinal Chemistry; Drug Discovery: From Screening to Clinical Candidate; Biologics for Challenging CNS Targets; and Commercialization Strategies: Developing Science into Products. Relevant examples for Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis will be included in the discussions. Sessions will consist of 20-30 minute presentations with ample time for Q&A, networking and poster sessions presented by young investigators. With respect to the public-private partnership initiative of the Roadmap, the ADDF will invite 27 internationally recognized scientists from academia, industry and NIH to serve as chairs or speakers. It is anticipated that this conference will serve 150 scientists from diverse backgrounds, including women, minorities, young/junior investigators and graduate students. PUBLIC HEALTH RELEVANCE: The public health problem the ADDF seeks to solve is to reduce the incidence of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. By offering this conference, the ADDF will increase scientists' knowledge of the drug discovery processes and catalyze them to work together to develop commercially viable and effective disease modifying therapies.